Global Biotech & Pharma Licensing Activity Falls Sharply in Q3 2012

Following a steady decrease the last two quarters, the number of drug licensing agreements for Q3 2012 has nearly halved.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Norwood, MA (PRWEB) October 15, 2012

BioPharm Insight’s Q3 2012 Licensing Activity and M&A League Tables report provides research and insight needed to evaluate market opportunities, market values and trends and competitive strategies. Sign up for a free trial to download the full reports.

Although the total disclosed value of licensing agreements involving pharmaceutical products has hardly changed from Q2 2012 levels, the total volume of deals fell sharply in Q3. The quarter saw 77 agreements valued at US$4,787m, a decrease of 43% by volume from Q2 2012, in which 135 agreements worth US$4,530m were announced. The agreement between Molecular Partners AG and Allergan Inc., involving the DARPin Ophthalmic Program, was the largest deal in Q3 2012, potentially valued at US$1,463m.

Latham & Watkins advised on six Biotech/Pharma M&A transactions valued at US$3,709m in Q3, five of which involved North American companies. In Europe, Mayer Brown tops both the value and volume table with two deals worth US$1,213m.

JPMorgan leads the global value and North American value & volume tables for Q3 with three deals worth US$5,337m, while Jefferies & Company tops the global volume table with four transactions priced at US$920m. In Europe, Barclays leads by both value and volume with two transactions worth US$1,258m. Citigroup tops the Asia-Pacific Q3 2012 value and volume tables with two deals priced at US$477m.

In early September, Valeant Pharmaceuticals International Inc., a Canada-based company, agreed to acquire Medicis Pharmaceutical Corporation, a listed US-based biopharmaceutical company focused on dermatological and aesthetic conditions, for US$2.6bn. The deal is expected to close in the first half of 2013.

In July, Fresenius Kabi AG, a Germany-based provider of infusion therapy and clinical nutrition, and a subsidiary of Fresenius SE & Co. KGaA, a listed Germany-based provider of products and services for dialysis, hospitals and outpatient medical care, agreed to acquire Fenwal Inc., a US-based blood transfusion technology company, for an estimated consideration of US$1,100m. The transaction is expected to close by the end of 2012.

On 16 July 2012, Thermo Fisher Scientific Inc. agreed to acquire One Lambda, Inc. for a total consideration of US$925m. Thermo Fisher Scientific Inc., a listed US-based company, is a manufacturer of analytical instruments that monitors, collects and analyzes information for a broad range of life science, laboratory and industrial customers. One Lambda, Inc., a US-based company, is engaged in transplant diagnostics services. The transaction is expected to close in the fourth quarter of 2012.

Sign up for a free trial to download the full reports.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides clients with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.

About Infinata, Inc.
Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, a Financial Times Group company, and a division of Pearson plc. To learn more, visit http://www.infinata.com


Contact